Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04918173 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
A Phase 3 study of Congenital Antithrombin Deficiency, sponsored by Octapharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 38
- Enrollment target
- 20
- Study locations
NCT04918173: Recruiting Phase 3 study of Congenital Antithrombin Deficiency, sponsored by Octapharma.
NCT04918173 is a Phase 3 study of Congenital Antithrombin Deficiency that is actively recruiting participants, run by Octapharma. The registered enrollment target is 38 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04918173, a Phase 3 study of Congenital Antithrombin Deficiency, is actively recruiting participants, sponsored by Octapharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 38 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical procedures or parturition.
Primary Outcome
The primary objective of this study is to assess the incidence of the composite of TEs and TEEs in patients with congenital antithrombin deficiency under cover of Atenativ for surgical procedures or parturition
Conditions Studied
Interventions
- DRUG Atenativ
Study Locations (20)
Other
- Yeolyan Hematology and Oncology Centre - Yerevan
- Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie und Hämostaseologie - Vienna
- Centre for Thrombosis and Haemaostasis - Nymburk
- Centre de Référence de l'Hémophilie Unité d'Hémostase Clinique Hôpital Cardiologique Louis Pradel - Bron
- University Hospital of Reims - Reims
- Centre Hospitalier Universitaire de Rouen (CHU de Rouen) - Centre de Traitement des Maladies Hemorragiques (CRTH) (Centre d'Hemophiles) - Rouen
- Aversi Clinic - Tbilisi
- Klinik fur Angiologie Hamostaseologie Haus 12 A Gerinnungssprechstunde - Berlin
- UKB Bonn Institut für Experimentelle Hämatologie und Transfusionsmedizin - Bonn
- Gerinnungszentrum Rhein-Ruhr - Duisburg
- University of Debrecen, Medical and Health Science Centre - Debrecen
- Rabin Medical Centre, Institute of Haematology - Petah Tikva
- Sheba Medical Centre - Ramat Gan
- Unita Strutturale Complessa di Immunoematologia e Medicina Trasfusionale -Dipartimento Interaziendale di Medicina Trasfusionale ed Ematologia - ASST Papa Giovanni XXIII ematologia Piazza OMS, 1 - Bergamo
- Universita degli Studi di Milano - IRCCS Ospedale Maggiore Policlinico - Centro Emofilia e Trombosi Angelo Bianchi Bonomi - Milan
District of Columbia
- Georgetown University - Washington D.C.
Florida
- University of Miami - Miami
Illinois
- Bleeding and Clotting Disorders Institute - Peoria
New York
- Weill Cornell Medicine - New York
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 3 |
What NCT04918173 shows while recruiting
NCT04918173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Congenital Antithrombin Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Atenativ is the first listed.
NCT04918173 names 20 study sites across 6 states, led by Other, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT04918173 about?
NCT04918173 is a clinical study titled "Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery". The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical procedures or parturition.
What is the current status of trial NCT04918173?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 38 participants. The study started on 2022-07-01. Estimated completion is 2026-06-01.
What conditions does trial NCT04918173 study?
This clinical trial studies the following conditions: Congenital Antithrombin Deficiency.
What interventions are being tested in trial NCT04918173?
The interventions under investigation include: Atenativ (DRUG).
Who is sponsoring clinical trial NCT04918173?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04918173 being conducted?
This trial has 20 study locations across District of Columbia, Florida, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04918173's enrollment target sits among peer trials
38 1901st of 2000 higher than 100 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI